Bristol Myers Squibb’s US$2.3bn Texas Manufacturing Campus
“Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” says Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of BMS.
“This facility is designed to deliver the speed, quality and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities.
“It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting to future demands.”
Significant investment in infrastructure
BMS has announced significant investment in its medicine development infrastructure in recent months.
Chief among these was scaling its NVIDIA-powered AI infrastructure to create the “most powerful AI factory in life sciences”.
Despite already possessing one of the industry’s most powerful AI systems, its next-gen system will deliver up to ten times greater performance per megawatt than its predecessor.
Also set for completion in 2026 is the company’s US$400m Sterile Drug Product facility at Cruiserath Campus in Dublin.
The investment will support manufacturing and supply of existing medicines and create 350 new jobs.
